Related Experiment Video
Updated: Feb 3, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Peptide-Based Radiopharmaceuticals for Molecular Imaging of Prostate Cancer
Tamila J Stott Reynolds1, Charles J Smith2, Michael R Lewis3
1Laboratory Animal Resources Center, University of Texas at El Paso, El Paso, TX, USA.
Abstract:
Given the high incidence of prostate cancer, there is a continuing need for advances in early detection and in effective treatments. Over the last several years, radiolabeled peptides have been developed, which can target receptors on prostate tumors with high affinity and specificity. These peptides are eliminated from normal tissues rapidly, producing high contrast for PET and SPECT imaging. Receptors of interest for tumor imaging include prostate specific membrane antigen (PSMA), gastrin-releasing peptide receptor (GRPR), and αvβ3 integrin. Because radiolabeled peptides afford high tumor-to-normal tissue uptake ratios, the potential of peptide-based targeted radiotherapy of prostate cancer is being explored. In addition, targeting either of two receptors with one peptide may allow more tumors to be detected and aid in the delineation of early versus advanced disease. Taken together, all these developments in peptide-based imaging and therapy of prostate cancer offer the promise of personalized, molecular medicine for individual patients.
Insights
Radiolabeled peptides offer promising advances in prostate cancer detection and treatment by targeting specific tumor receptors. These agents enhance imaging contrast and show potential for targeted radiotherapy, paving the way for personalized medicine.
Area of Science:
- Oncology
- Radiochemistry
- Molecular Imaging
Background:
- Prostate cancer necessitates improved early detection and treatment strategies.
- Radiolabeled peptides targeting specific tumor receptors have emerged as a significant advancement.
- These peptides demonstrate high affinity and specificity for prostate tumors, with rapid clearance from normal tissues.
Purpose of the Study:
- To review the development and potential applications of radiolabeled peptides in prostate cancer.
- To highlight the role of specific receptors like prostate specific membrane antigen (PSMA), gastrin-releasing peptide receptor (GRPR), and αvβ3 integrin in targeted imaging and therapy.
- To discuss the promise of dual-receptor targeting peptides for enhanced tumor detection and disease staging.
Main Methods:
- Development of novel radiolabeled peptides targeting key prostate cancer receptors.
- Evaluation of peptide affinity, specificity, and pharmacokinetic profiles.
- Assessment of imaging contrast (PET/SPECT) and therapeutic potential (radiotherapy).
Main Results:
- Radiolabeled peptides achieve high tumor-to-normal tissue uptake ratios, enabling clear imaging.
- Specific receptors (PSMA, GRPR, αvβ3 integrin) are viable targets for peptide-based agents.
- Exploration of peptide-based targeted radiotherapy shows promising potential.
Conclusions:
- Radiolabeled peptides represent a significant advancement in prostate cancer diagnostics and therapeutics.
- These agents facilitate personalized, molecular medicine approaches for individual patients.
- Future developments may enhance tumor detection, staging, and treatment efficacy.
Related Concept Videos
02:43Peptide Bonds
02:00Molecular Models
03:10Molecular Compounds: Formulas and Nomenclature
03:51Molecular Orbital Theory II
02:35Molecular Orbital Theory I
02:27Predicting Molecular Geometry